Clinical trials: Breakthrough Cancer Pain
Pain, Cancer
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00492388
- Testing
- PMI-150 (intranasal ketamine)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Pain, Cancer
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain associated with cancer, sickle cell disease, or…
- Conditions
- Pain, Cancer, Sickle Cell Anemia, Severe Burns
- Trial name
- NCT00236093
- Testing
- ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
- Where
- 28 sites in United States, Canada and 1 more
- Sponsor
- Cephalon
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cancer, Breakthrough Cancer Pain
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control.
- Trial name
- REBORN (NCT03564548)
- Testing
- PPP001, Morphine sulfate or Hydromorphone or Oxycodone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tetra Bio-Pharma
Quality of Life, Breakthrough Cancer Pain
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough…
- Trial name
- RELIEF (NCT01936636)
- Testing
- Fentanyl
- Where
- 36 sites in United States
- Volunteers
- 164 people
- Sponsor
- Galena Biopharma, Inc.
Cancer, Breakthrough Pain
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the management of breakthrough pain (BTP) compared to placebo treatment in children with cancer and non-cancer pain who are receiving…
- Trial name
- NCT00236041
- Testing
- ACTIQ®
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- Cephalon
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Pain, Cancer
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
- Trial name
- NCT00262678
- Testing
- EN3267
- Where
- United States
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Predictable BTP at Swallowing in in Head/Neck Cancer Patients Undergoing Radiotherapy Already Receiving Opioid Therapy for Background Pain
PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy
The primary objective of the present phase IIIb study is to assess the efficacy of FPNS compared with Physician Choice-Usual Care (PC-UC) in the reduction of swallowing predictable BTP in head and neck cancer patients undergoing…
- Trial name
- PERFECT FAST (NCT01980498)
- Testing
- Fentanyl pectin nasal spray (FPNS), Physician choice-Usual care (PC-UC)
- Where
- 25 sites in Italy
- Sponsor
- L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01693328)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Archimedes Development Ltd
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment.
- Trial name
- CAVIDIOM (NCT03435120)
- Testing
- No intervention
- Where
- 14 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Angelini Farmacéutica
Pain
Conversion From Fast Acting Oral Opioids to Abstral®
The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer…
- Trial name
- NCT01315886
- Testing
- SL fentanyl
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Orexo AB
Pain
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00576173
- Testing
- tramadol hydrochloride; acetaminophen
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Breakthrough Pain, Cancer
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
- Trial name
- ETHYFYL (NCT01842893)
- Testing
- Fentanyl Ethypharm
- Where
- Czechia
- Volunteers
- 91 people
- Sponsor
- Ethypharm
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.
- Trial name
- NCT05531422
- Testing
- Inhaled fentanyl aerosol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Lee's Pharmaceutical Limited
Breakthrough Cancer Pain
Safety of Fentanyl TAIFUN Treatment
A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain…
- Trial name
- FINDS (NCT00822614)
- Testing
- Fentanyl TAIFUN, Opioid
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Akela Pharma, Inc.
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.